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T cells expressing chimeric antigen receptors (CARs) or the infusion of bispecific T-cell engagers (BITEs) 
have shown antitumor activity in humans for CD19-positive malignancies. While BITEs redirect the 
large reservoir of resident T cells to tumors, CAR T cells rely on significant in vivo expansion to exert 
antitumor activity. We have shown that it is feasible to modify T cells to secrete solid tumor antigen-
specific BITEs, enabling T cells to redirect resident T cells to tumor cells. To adapt this approach to CD19-
positive malignancies we now generated T cells expressing secretable, CD19-specific BITEs (CD19-ENG T 
cells). CD19-ENG T cells recognized tumor cells in an antigen-dependent manner as judged by cytokine 
production and tumor killing, and redirected bystander T cells to tumor cells. Infusion of CD19-ENG T 
cells resulted in regression of leukemia or lymphoma in xenograft models and a survival advantage in 
comparison to control mice. Genetically modified T cells expressing engager molecules may present a 
promising addition to current CD19-targeted immunotherapies.
The treatment of CD19-positive hematological malignancies including acute lymphoblastic leukemia (ALL) 
and Non-Hodgkin Lymphoma (NHL) has made great strides in the last decades1–4. However, current treatment 
regimens are associated with significant acute and long-term toxicities5. In addition, patients with recurrent 
or chemotherapy refractory disease have a poor prognosis6, highlighting the need to develop new therapeutic 
approaches that improve outcomes and reduce treatment-related complications for all patients.
Promising immunotherapy approaches for CD19-positive hematological malignancies include the adoptive 
transfer of T cells that are genetically modified to express CD19-specific chimeric antigens receptors (CARs) or 
the infusion of bispecific antibodies that redirect resident T cells to CD197–15. The most successful bispecific anti-
bodies in clinical studies are bispecific T-cell engagers (BITEs), which consist of 2 single chain variable fragments 
(scFVs) connected by a short linker15. While the CD19-specific BITE blinatumomab received FDA approval in 
201416,17, BITEs have a short half-life, requiring continuous infusion that may be associated with toxicities, lack 
active biodistribution, and inability to self-amplify18,19. One potential strategy to overcome these limitations is the 
genetic modification and adoptive transfer of T cells that secrete diabodies20 or T-cell engagers (ENG T cells)21, 
since T cells can actively secrete molecules at tumor sites, and persist for several weeks post infusion. While ENG 
T cells have been explored in preclinical models for solid tumors21, no data is currently available for hematological 
malignancies. In this study, we characterize ENG T cells specific for CD19-positive malignancies (CD19-ENG 
T cells) and show that they are activated and kill tumor cells in an antigen dependent manner, are able to recruit 
bystander T cells to tumor cells, and have antitumor activity in preclinical models.
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Materials and Methods
Cell lines and culture conditions. The Ph-positive acute B lymphoblastic leukemia (ALL) cell line BV173 
(German Collection of Microoganisms and Cell Cultures, Braunschweig, Germany) and Burkitt’s lymphoma 
cell lines Daudi and Raji (ATCC, Manassas, VA) were used as CD19-positive targets. The generation of firefly 
luciferase (ffLuc)-expressing BV173 (BV173.ffLuc) and Daudi (Daudi.ffLuc) cells were described previously22,23. 
K562 (chronic myelogenous leukemia, ATCC) and A549 (lung carcinoma, ATCC) cell lines were used as negative 
controls. All cell lines were grown in RPMI 1640 (Thermo Scientific). 293T cells (ATCC) were used for packaging 
retroviral vectors and grown in DMEM. All media was supplemented with 10–20% FBS (Thermo Scientific) and 
2 mmol/L GlutaMAX-I (Invitrogen, Carlsbad, CA).
Construction of retroviral vectors encoding T-cell enganger molecules. The construction of the 
CD19-specific engager molecule has been previously reported21. Briefly, a mini gene encoding a CD19-specific 
engager molecule containing the immunoglobulin heavy-chain leader peptide, the CD19-specific scFv 
(FMC63)24, a short serine-glycine linker, and a CD3-specific scFV derived from OKT3 was synthesized by 
Invitrogen (Carlsbad, CA) and subcloned into pSFG-IRES-mOrange (provided by Dr. Vera, Baylor College of 
Medicine). The retroviral vector encoding the EphA2-specific T-cell engager was generated in a similar fash-
ion using the EphA2-specific scFv 4H525. RD114-pseudotyped retroviral particles were generated as previously 
described26.
Generation of Engager T cells. All methods involving human subjects were carried out in accordance 
to the Declaration of Helsinki. Human peripheral blood mononuclear cells (PBMCs) from healthy donor were 
obtained under a Baylor College of Medicine IRB approved protocol, after acquiring informed consent. PBMCs 
were stimulated on OKT3 (1 μ g/mL, CRL-8001, ATCC) and CD28 (1 μ g/mL, BD Bioscience) antibodies-coated 
non-tissue culture treated 24-well plates. Human interleukin 2 (IL2) (200 U/mL, Biological Research Branch, 
National Cancer Institute, Frederick, MD) was added to cultures on day 2, and on day 3 T cells were transduced 
with retroviral particles on RetroNectin (Clontech) coated plates in the presence IL2 (100 U/mL). T cells were 
subsequently expanded with IL2. Non-transduced (NT) T cells were activated with OKT3/CD28 and expanded in 
parallel with IL2. Cells were cultured for 7–10 days prior to being used for in vitro or in vivo experiments.
Flow cytometric analysis. The expression of mOrange was detected by FACS analysis. For immunopheno-
typing, cells were stained with CD3-PerCP, CD4-FITC, and CD8-FITC monoclonal antibodies (BD Biosciences, 
Mountain View, CA). Isotype controls were IgG1-FITC and IgG1-PerCP (both Becton Dickinson, Mountain 
View, CA). CD19-specific T-cell engagers were detected using a CD19 scFv-specific ID antibody27 and an APC 
Goat antimouse IgG antibody (BD Biosciences)27. For each sample, 20,000 cells were analyzed by a FACSCalibur 
instrument (BD Biosciences) using Cell Quest Software (BD Biosciences).
Bioassay. NT T cells and Raji cells were plated in a 96 well plate at a 1:1 ratio (1 × 105/well) in 100 μ l of 
complete RPMI. Next 100 μ l of serially diluted recombinant CD19xCD3-bispecific engager protein (GenScript, 
Piscataway, NJ) or conditioned media (obtained from ENG T cells cultured for 24 hour at a concentration of 
1 × 106/mL) were added. The 96 well plates were incubated for 14 to 16 hours prior to determining interferon 
(IFN)γ using an ELISA kit as per the manufacturer’s instructions (R&D Systems, Minneapolis, MN). To deter-
mine the ENG concentration in conditioned media a standard curve was constructed using the IFNγ values 
obtained with serially diluted recombinant CD19-/CD3-specific engager protein.
Coculture assays. CD19-ENG and EphA2-ENG T cells were plated at a 2:1 ratio with CD19-positive (Daudi, 
Raji, BV173) or -negative (K562) target cells. Coculture supernatant was collected after 48 hours and used for 
cytokine analysis. IFNγ and IL2 concentrations were determined using ELISA kits (R&D Systems, Minneapolis, 
MN) according to the manufacturer’s instructions.
Cytotoxicity assay. Cytotoxic activity of ENG T cells against targets was determined by standard 51Cr 
release assay. 1 × 106 target cells were labeled with 50μ Ci 51Cr and incubated for 1 hour. Targets were then washed 
and 5 × 103 cells were cocultured with effector T cells at different effector to target (E:T) ratios. Supernatants were 
analyzed with a Packard Cobra Quantum gamma counter Model E 5010 (Perkin Elmer, Shelton CT) reader after 
4 hour incubation. Lysis was calculated as previously described21.
Transwell Assay. To show that CD19-ENG T cells were able to recruit bystander (non-transduced) T cells 
we performed transwell assays with GFP.ffLuc-expressing target cells using inserts (6.5 mm in diameter, 0.4 μ m 
pore, polycarbonate, Corning, Corning, NY), which allow for small molecule diffusion but not cell migration. 
Luciferase activity was determined according to the manufacturer’s instructions using a luciferase assay kit 
(Promega, Madison, WI) and a Monolight 3010 luminometer (BD Biosciences).
In vivo experiments. Animal experiments were performed on a protocol approved by the Baylor College 
of Medicine Institutional Animal Care and Use Committee in accordance to the American Association for 
Laboratory Animal Science. Eight to 10 week old NSG mice (NOD.Cg-Prkdcscid/Il2rgtm1Wjl/SzJ; JAX Mice, 
Bar Harbor, ME) were sublethally irradiated with 120 cGy 24 hours before the intravenous (i.v.) injection of 
3 × 106 BV173.ffLuc cells. Mice were treated i.v. with 1 × 107 CD19-ENG or EphA2-ENG T cells on days 7, 14, 
and 21 after tumor cell injection. Cell count of infused cells was based on total cell number. Untreated animals 
served as controls. As indicated, animals received one intraperitoneal (i.p.) dose of 1,500 units IL2 (Biological 
Research Branch, National Cancer Institute, Frederick, MD) on the day of the T-cell injections. At indicated 
time points blood was collected by retro-orbital bleeding. Serum cytokine concentrations were determined using 
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Milliplex MAP High Sensitivity Human Cytokine Panel – Premixed 13 Plex (EMD Millipore, Billerica, MA) as 
per manufacturer’s instructions. In the systemic Daudi model, mice received i.v. 2 × 106 Daudi.ffLuc cells followed 
by 1 × 107 i.v. T-cell injections on days 3, 6 and 9. In the local Daudi model, mice were injected i.p. with 2.5 × 106 
Daudi cells in the right lower quadrant, and 14 days later received i.v. 3 × 106 T-cells CD19-ENG or EphA2-ENG 
T-cells that were also genetically modified to express eGFP.ffLuc. Mice were imaged using the IVIS® system (IVIS, 
Xenogen Corp., Alameda, CA) as previously described22, and euthanized at predefined endpoints or when they 
met euthanasia criteria in accordance with the Center for Comparative Medicine at Baylor College of Medicine.
Figure 1. Generation of CD19-ENG T-cells. (a) Retroviral construct used to generate CD19 ENG T cells.  
(b,c) Five to 7 days after transduction, mOrange expression was measured by flow cytometry, and 60.4 ± 16% 
of the T-cells were mOrange positive (n = 24; range 35–87%; 95% CI 53.7–67.2). (D) A CD19-specific scFv Id 
antibody was used to detect CD19-ENG molecules. mOrange-positive and negative T cells stained positive 
(filled curve) for CD19-ENG in contrast to samples that were stained with secondary antibody alone (open 
curve). EphA2-ENG T cells were not stained by the CD19-specific scFv Id antibody, confirming specificity.  
(e,f) The concentration of CD19-ENG in media from CD19-ENG or EphA2-ENG T cells was determined using 
a coculture bioassay. (e) A standard curve was generated using recombinant CD19xCD3 protein. (f) CD19-ENG 
T-cell media had CD19-ENG protein concentrations ranging 39.7–223 ng/mL; (95%CI 46.6–212.3). No CD19-
ENG molecules were detected in media of EphA2-ENG T cells.
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Figure 2. In vitro characterization of CD19-ENG T cells. (a,b) CD19-ENG or EphA2-ENG T cells were 
cocultured with CD19-positive (BV173, Daudi, Raji) or -negative (K562) tumor cells at a ratio of 2:1. After 
48 hours, IFNγ and IL2 production was determined by ELISA (n = 3; assay performed in duplicates; *p < 0.05;  
**p < 0.01; ***p < 0.001; NS: not significant). (c) Cytotoxicity assays were performed using CD19-ENG, EphA2-
ENG, and NT T cells as effectors and CD19-positive (BV173, Daudi, Raji) and negative (K562) tumor cells 
as targets at a E:T ratio of 2.5:1 (mean + SD; n = 3; assay was performed in duplicates; BV173, Raji, or Daudi: 
CD19-ENG vs EphA2-ENG T cells: * p < 0.001; CD19-ENG vs NT T cells: * p < 0.001; K562: CD19-ENG vs 
EphA2-ENG T cells: NS; CD19-ENG vs NT T cells: NS).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:27130 | DOI: 10.1038/srep27130
Statistical analysis. GraphPad Prism 5 software (GraphPad software, Inc.) was used for statistical analysis. 
Measurement data were presented as mean ± standard deviation (SD). For comparison between two groups, 
two-tailed t-test was used. For comparisons of three or more groups, the values were analysed by one-way 
ANOVA with Bonferroni’s post-test. For the mouse experiments, survival, determined from the time of tumor 
cell injection, was analysed by the Kaplan–Meier method and by the log-rank test.
Results
Generation of CD19-ENG T cells. T cells were transduced with a retroviral vector encoding a CD19-
specific T-cell engager an IRES and mOrange (Fig. 1a). Five to 7 days after transduction, mOrange expression was 
measured by flow cytometry, and 60.4 ± 16% of the T cells were positive (n = 24; range 35–87%; 95% CI 53.7–67.2, 
Fig. 1b,c). Both mOrange-positive and -negative T cells had CD19-ENG molecules bound to their cell surface 
as judged by FACS analysis using a CD19-specific scFv Id antibody, indicating that CD19-ENG molecules are 
secreted from transduced cells and then bind to CD3 on the T-cell surface. T cells expressing an ENG molecule 
specific for an irrelevant antigen (EphA2; EphA2-ENG T cells) were not stained confirming specificity (Fig. 1d).
To quantify secretion of CD19-ENG molecules by CD19-ENG T cells, we used a coculture bioassay. While 
media of CD19-ENG T cells contained 129.4 ± 79.0 ng/ml CD19-ENG molecules (range 39.7–223 ng/mL; 95%CI 
46.6–212.3), no CD19-ENG molecules were detected in media from T cells secreting an ENG specific for an irrel-
evant tumor antigen (EphA2-ENG T cells; Fig. 1e,f). Thus, our results demonstrate that it is feasible to generate T 
cells that secrete CD19-ENG molecules.
CD19-ENG T cells recognize and kill CD19-positive target cells in antigen dependent manner. 
To evaluate if CD19-ENG T cells recognize CD19-positive target cells we performed coculture assays. CD19-ENG 
T cells secreted IFNγ after coculture with CD19-positive tumor cells (BV173, Daudi, Raji) while EphA2-ENG T 
cells did not (p < 0.001; Fig. 2a). Significant IL2 production was only observed in the presence of CD19-positive 
Raji and Daudi cells (Fig. 2b), which express co-stimulatory molecules such as CD80 and CD86, in contrast 
to BV173 cells (Supplementary Fig. 1). In cytotoxicity assays CD19-ENG T cells killed CD19-positive but not 
CD19-negative cells (Fig. 2c). NT and EphA2-ENG T cells had no cytolytic activity confirming the specificity of 
CD19-ENG T cells. These results indicate that CD19-ENG T cells recognize tumor cells in an antigen-dependent 
manner as judged by cytokine production and tumor killing.
CD19-ENG T cells redirect bystander T cells to CD19-positive target cells. To demonstrate that 
CD19-ENG T cells were able to recruit bystander T cells to CD19-positive targets we used transwell assays. 
BV173.ffLuc cells were plated with or without NT T cells in the bottom well, and ENG T cells or NT T cells were 
plated in the insert well (Fig. 3a). Tumor cell killing was dependent on the presence of NT T cells in the bottom 
well and CD19-ENG T cells in the insert well, indicating that T cells secrete ENG molecules to redirect NT T cells 
to CD19-positive targets (Fig. 3b). No cell killing was observed if EphA2-ENG or NT T cells were plated in insert 
wells, indicating that killing was antigen specific. To further demonstrate that bystander T-cell killing does not 
depend on T cells that produce the engager molecules, we expressed CD19-ENG or EphA2-ENG in NK cells, and 
performed cytotoxicity assays. CD19-ENG NK cells were able to induce BV173 killing in the presence of T cells, 
indicating that ENG-secreting cells that are not activated themselves by ENG molecules can redirect bystander 
Figure 3. CD19-ENG T cells are able to recruit bystander T cells. (a) Schematic representation of transwell 
assay. (b) 1 × 106 NT T-cells and 0.5 × 106 BV173.ffLuc cells were plated in the bottom well and CD19-ENG T 
cells in the insert well. The number of plated CD19-ENG T cells ranged from 103 to 106. EphA2-ENG T cells or 
media in the insert well and bottom wells without NT T cells served as controls. After 48 hours, live BV173.ffLuc 
cells were determined by luciferase assay (n = 3; *p < 0.05; **p < 0.01).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:27130 | DOI: 10.1038/srep27130
T cells to tumor cells. Unmodified NK cells, or modified to secrete EphA2-ENG did not induce target cell killing 
(Supplementary Fig. 2). Thus, the results presented in this section demonstrate that ENG-secreting cells redirect 
bystander T cells to tumor cells in an antigen-dependent manner.
CD19-ENG T cells have potent antitumor activity in vivo. We evaluated the antitumor activity of 
CD19-ENG T cells in the i.v. BV173 leukemia NSG xenograft model. Mice received 1 × 107 CD19-ENG T cells 
or EphA2-ENG T cells i.v. with one i.p. dose of 1500 IU IL2 on days 7, 14, and 21 post tumor cell injection. 
CD19-ENG T cells eradicated BV173 cells (Fig. 4a,b) resulting in disease-free survival of all mice in contrast to 
untreated mice and mice treated with EphA2-ENG T-cells (p < 0.05; Fig. 4c), which lost weight (Fig. 5a) and died 
within 40 days of BV173 injection.
Figure 4. CD19-ENG T cells have potent antitumor activity in vivo. Antitumor activity of CD19-ENG 
T cells in the i.v. BV173 leukemia NSG xenograft model. Mice received an i.v. dose of 1 × 107 CD19-ENG 
(n = 5) or EpHA2-ENG T cells (n = 5) and an i.p. dose of IL2 (1500 units) 7, 14, and 21 days after i.v. injection 
of 3 × 106 BV173.ffLuc cells. Untreated animals served as controls (n = 5). Tumor growth was followed by 
bioluminescence imaging. (a) Images of animals. (b) Quantitative bioluminescence imaging results for each 
mice (radiance = photons/sec/cm2/sr) over time (p < 0.05 starting day 6 post 1st T-cell injection for CD19-ENG  
vs EphA2-ENG T cells, and CD19-ENG T cells vs controls). (c) Kaplan-Meier survival curve (Control vs 
EphA2-ENG T cells: NS; Control vs CD19-ENG T cells: p = 0.0019; EphA2-ENG vs CD19-ENG T cells: 
p = 0.0021).
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To determine if leukemia control was achieved without prolonged, systemic exposure to ENG molecules we 
determined the concentration of CD19-ENG in the peripheral blood of mice at baseline and prior to the 2nd and 
3rd infusion T-cell infusion. ENG molecules were only present at low levels (107 pg/ml, 116 pg/ml) in 2 out of 5 
samples before the 3rd T-cell infusion (Fig. 5b). To assess safety, we determined the presence of human cytokines 
in the peripheral blood of mice at the same time points. While we could detect low levels of GM-CSF, IFNγ , IL5, 
or IL7 prior to the 2nd and 3rd T-cell infusion (median: 19 pg/ml; range: 0–234 pg/ml), no increase of all other 
measured cytokines (IL1β , IL2, IL4, IL6, IL8, IL10, IL12(p70), IL13, TNFα ) was observed (Fig. 5c,d).
Having established that 3 doses of CD19-ENG T cells in conjunction with a single dose of IL2 can safely eradi-
cate leukemia, we determined the minimal effective dose of CD19-ENG T cells without IL2. Mice were treated on 
day 7 with 1 × 106, 3 × 106 or 1 × 107 CD19-ENG T cells. While 1 × 106 or 3 × 106 T cells were ineffective, 3 out of 
5 mice treated with 1 × 107 CD19-ENG T cells had a response with 2 being complete (Fig. 6a,b).
To investigate if the antitumor activity of CD19-ENG T cells depended on significant T-cell expansion we 
injected BV173 leukemia-bearing mice on day 7 with 1 × 107 CD19-ENG or EphA2-ENG T cells that were 
genetically modified with a 2nd retroviral vector encoding eGFP.ffLuc (Supplementary Fig. 3). While nei-
ther EphA2-ENG or CD19-ENG T cells expanded in vivo as judged by bioluminescence imaging (Fig. 6c,d), 
CD19-ENG T cells persisted longer resulting in a significant difference (p < 0.05) in bioluminescence imaging 
day 2 and 3 post T-cell injection in comparison to EphA2-ENG T cells.
To explore if CD19-ENG T cells home to tumor sites and expand in the presence of costimulatory molecules 
we used a local Daudi model in which tumor cells were injected I.P. in the right lower quadrant. On day 14 post 
Figure 5. Safety profile of CD19-ENG T cells. (a) Untreated (Control) and mice treated with EphA2-ENG 
T cells started to lose weight and died before day 40, the weight of mice treated with CD19-ENG T cells 
remained stable throughout the experiment. (b) Before the 1st, 2nd and 3rd T-cell infusion blood from BV173 
leukemia-bearing mice treated with CD19-ENG T cells (n = 5) was collected by retro-orbital bleeding and 
the concentration of ENG molecules was determined using our bioassay. Only two of 5 samples pre 3rd T-cell 
infusion had detectable concentration of engager molecules in their blood. (c,d) At the same time points 
cytokines were determined using a Milliplex MAP High Sensitivity Human Cytokine Panel – Premixed 13 Plex 
(EMD Millipore, Billerica, MA) as per the manufacturer’s instructions. (c) GM-CSF, IFNγ , IL5, and IL7 were 
detectable at low levels (median: 19 pg/ml; range: 0–234 pg/ml) before the 2nd and 3rd infusion. (D) IL1b, IL2, 
IL4, IL6, IL8, IL10, IL12(p70), IL13, TNFα ) were undetectable.
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tumor cell injection, mice received 3 × 106 eGFP.ffLuc-expressing CD19-ENG or EphA2-ENG T cells. Non-tumor 
bearing mice receiving 3 × 106 eGFP.ffLuc-expressing CD19-ENG T cells served as controls. CD19-ENG or 
EphA2-ENG T cells homed to tumor sites (Fig. 7a), and CD19-ENG T cells proliferated immediately in contrast 
to EphA2-ENG T cells as judged by bioluminescence imagining, indicative of antigen-dependent T-cell expan-
sion (Fig. 7a,b). Starting day 14, there was a decline in bioluminescence signal of CD19-ENG T cells. CD19-ENG 
T-cell infused mice continued to grow with no significant change in weight in comparison to non-tumor bearing 
control mice (Fig. 7c). In contrast, EphA2-ENG T cells started to proliferate on day 6 post T-cell injection. While 
the bioluminescence signal continued to increase, mice developed visible tumors in the right lower quadrant, and 
ascites as judged by a significant weight gain (EphA2-ENG T cells + Daudi vs CD19-ENG T cells or EphA2-ENG 
T cells + Daudi: p < 0.05 starting day 25), necessitating euthanasia on day 39 post EphA2-ENG T-cell injection.
Figure 6. CD19-ENG T cells do not expand in the BV173 model in vivo and antitumor activity depends 
on T-cell dose. (a,b) Seven days after i.v. injection of 3 × 106 BV173.ffLuc cells mice received a single i.v. 
dose of 1 × 106, 3 × 106, or 1 × 107 CD19-ENG T cells (n = 5 mice per group). Tumor growth was followed by 
bioluminescence imaging. (a) Quantitative bioluminescence imaging results for each mice (radiance = photons/
sec/cm2/sr). (b) Kaplan-Meier survival curve (1 × 107 vs 3 × 106 CD19-ENG T cells: p = 0.02; 1 × 107 vs 1 × 106 
CD19-ENG T cells: p = 0.02; 3 × 106 vs 1 × 106 CD19-ENG T cells: p = NS). (c,d) eGFP.ffLuc expressing  
CD19-ENG or EphA2-ENG T cells were injected i.v. into NSG mice 7 days after i.v. BV173 tumor-cell injection 
(n = 5 mice per group). Day 2 and 3 post T-cell injection there was a significant difference (*p < 0.05) between 
both groups.
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Discussion
Here we describe the generation of CD19-ENG T cells and demonstrate that these cells recognize and kill 
CD19-positive target cells in an antigen-dependent manner, redirect ‘bystander’ T cells to CD19-positive target 
cells, and have potent antitumor activity in vivo.
Modifying T cells with CARs or α β T-cell receptors (TCRs) is an attractive strategy to readily generate 
tumor-specific T cells ex vivo28,29, and early phase clinical studies have shown impressive clinical responses espe-
cially for CD19-positive hematological malignancies. However, these genetic modification strategies do not redi-
rect resident, bystander T cells to tumor cells. We and others had previously shown than T cells can be genetically 
modified with diabodies or bispecific T-cell engagers to redirect modified T cells and bystander T cells to solid 
tumor antigens such EphA2 or CEA20,21. We now extend these findings to CD19 and demonstrate that T cells, 
which are genetically modified to secrete CD19-specific T-cell engagers and demonstrate their potent effector 
function ex vivo and in vivo.
T cells were readily transduced by our retroviral vector encoding the CD19-ENG molecule and mOrange as 
judged by mOrange expression. We confirmed the secretion of CD19-ENG molecules using a bioassay. While 
bioassays are routinely used to quantify the biological activity of cytokines30, we are planning to develop an ELISA 
in the future to directly measure the CD19-ENG molecule protein concentration. CD19-ENG T cells recognized 
CD19-positive target cells in coculture assays as judged by cytokine production and cytolytic activity. However, 
Figure 7. CD19-ENG T cells expand locally in the Daudi model in vivo. On day 14 post right lower quadrant 
I.P. injection of Daudi cells, mice received 3 × 106 eGFP.ffLuc-expressing CD19-ENG or EphA2-ENG T cells. 
Non-tumor bearing mice that received 3 × 106 eGFP.ffLuc-expressing CD19-ENG served as controls. (a) Images 
of animals. (b) Quantitative bioluminescence imaging results (radiance = photons/sec/cm2/sr; mean + /− SD  
is shown). CD19-ENG T cells + Daudi vs EphA2-ENG T cells + Daudi: p < 0.05 from day 3 to day 14; CD19-ENG  
T cells + Daudi vs CD19-ENG T cells: p < 0.05 starting day 3 until day 32. (c) Weight (mean + /− SD) for all 
three mice groups (EphA2-ENG T cells + Daudi vs CD19-ENG T cells or CD19-ENG T cells + Daudi: p < 0.05 
starting day 25; CD19-ENG T cells + Daudi vs CD19-ENG T cells: p = NS).
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consistent IL2 production by CD19-ENG T cells was dependent on the presence of co-stimulatory molecules on 
the cell surface of target cells. Target-dependent IL2 production was also observed in our previous study with 
EphA2-ENG T cells, in which we observed in vivo T-cell expansion for the cell line that induced the highest 
amount of IL2 production of ENG T cells21. Indeed, while we did not observe in vivo expansion of CD19-ENG 
T cells in the BV173 model, we observed significant in vivo T-cell expansion in the Daudi model, in which the 
lymphoma cells express costimulatory molecules. Thus, robust IL2 production of ENG T cells after target cell 
encounter most likely predicts their ability to proliferate in vivo. Provision of costimulation could be achieved by 
expressing either costimulatory molecules such as CD80 or CD137L on the cell surface of T cells31 or a second 
engager molecule with a costimulatory domain32. Both strategies would provide costimulation to the genetically 
modified T cells, as well as to bystander T cells that are in close proximity.
CD19-ENG T cells had potent antitumor activity in the i.v. BV173 leukemia model and in the localized 
Daudi model. We confirmed the antitumor activity of CD19-ENG T cells in the systemic Daudi model in which 
NSG mice were injected i.v. with Daudi.ffLuc cells, and were treated i.v. with 3 doses of CD19-ENG or NT T 
cells (Supplementary Fig. 4). Side effects of CD19-targeted immunotherapies with CD19-CAR T cells or bli-
natumomab include fever, malaise, cytokine release syndrome (CRS), and neurotoxicity14. In all three models, 
CD19-ENG T cells infused mice did not lose weight, and for the BV173 model we also demonstrated that trough 
cytokine levels are not elevated; in addition, we could not detect circulating CD19-ENG molecules prior to each 
T-cell infusion. Clearly, a detailed time course of cytokine and ENG molecule concentration in the peripheral 
blood of infused mice is needed in the BV173 and Daudi model to confirm our findings in the future. However, it 
is important to note that significant side effects were not observed with CD19-CAR T cells and blinatumomab in 
preclinical animal models33,34, highlighting the inherent limitations of xenograft models for the study of human T 
cells. An immunocompetent animal model would most likely be more realistic for additional efficacy and safety 
studies of CD19-ENG T cells and to determine how these adoptively transferred cells interact with the resident 
immune system8,33,35–37. In this regard we have generated murine T cells expressing murine T-cell engagers based 
on the activating, murine CD3ε monoclonal antibody 2C11, but were unsuccessful to express sufficient amounts 
of T-cell engagers to induce antigen-dependent murine T-cell activation (Rodriguez-Cruz et al. unpublished 
observation).
In summary, our study shows that CD19-ENG T cells have potent antitumor effects, and have the unique 
ability to redirect resident T cells to CD19-positive hematological malignancies. Given the ability to introduce 
multiple genes into T cells38,39, it should be feasible to further increase the potency of ENG T cells by transgenic 
expression of cytokines or costimulatory molecules31,39,40, or increase their safety by introducing a suicide gene 
such as inducible caspase 9 41. Thus, ENG T cells may be a promising addition to current CD19-targeted immu-
notherapy approaches that either rely on the continuous infusion of recombinant protein or the adoptive transfer 
of CAR T cells.
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